View More Recent Stories
-
uniQure reports enzyme increases in Fabry disease gene therapy trial
-
Mizuho Upgrades uniQure BV (QURE) to Outperform
-
uniQure (QURE) defended at Mizuho
-
uniQure (QURE) Tops Q2 EPS by 20c
-
uniQure (QURE) spreader of 2500 contracts of October 15 and 30 calls
-
Stifel on uniQure BV (QURE): 'we are optimistic that the upcoming 3-year AMT-130 analysis is likely to look strong'
-
uniQure (QURE) Appoints Kylie O’Keefe as Chief Customer and Strategy Officer
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
Stifel Reiterates Buy Rating on uniQure BV (QURE)
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Provides Regulatory Update on AMT-130 for Huntington’s Disease
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Tops Q1 EPS by 18c
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
Increasing unusual call option volume: XND HTZ QURE KEY TMC CAR ALHC GPN AGL HDB IBN
-
uniQure (QURE) Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
-
Chardan Capital Markets Assumes uniQure BV (QURE) at Buy, PT $38
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the
-
uniQure (QURE) Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II Trial of AMT-162
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Prices 4.41M Share Offering at $17/sh
-
uniQure (QURE) Announces Proposed Share and Warrant Offering
-
uniQure (QURE) Files Mixed Shelf
-
7 top biotech picks for 2025 according to Wells Fargo
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
uniQure BV (QURE) PT Raised to $20 at Mizuho
-
uniQure BV (QURE) PT Raised to $20 at RBC Capital as 'FDA Leniency Materially De-risks HD'
-
Goldman Sachs Reiterates Neutral Rating on uniQure BV (QURE)
-
Increasing unusual call option volume: RGTI QURE GSAT CRDF PL QUBT ALK KULR BRZE QBTS UNFI UAA XP SFIX MTN
-
Raymond James Upgrades uniQure BV (QURE) to Strong Buy
-
Increasing unusual call option volume: QURE RGTI PL KULR BRZE UNFI VSTS MTN ASAN QUBT
-
Stifel on uniQure (QURE): 'we believe this is a big win for the stock'
-
uniQure (QURE) Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
-
uniQure (QURE) Tops Q3 EPS by 11c
-
uniQure (QURE) Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
-
Raymond James Resumes uniQure BV (QURE) at Outperform
-
uniQure (QURE) Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
Increasing unusual option volume: EWC QURE SGH HA LZ UROY RGTI
-
uniQure (QURE) call put ratio 3 calls to 1 put amid share price up 65%
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
TD Cowen Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
-
uniQure (QURE) to Sell Gene Therapy Manufacturing Operations in Lexington, MA to Genezen
